AU2002314861A1 - Targeted multivalent macromolecules - Google Patents
Targeted multivalent macromoleculesInfo
- Publication number
- AU2002314861A1 AU2002314861A1 AU2002314861A AU2002314861A AU2002314861A1 AU 2002314861 A1 AU2002314861 A1 AU 2002314861A1 AU 2002314861 A AU2002314861 A AU 2002314861A AU 2002314861 A AU2002314861 A AU 2002314861A AU 2002314861 A1 AU2002314861 A1 AU 2002314861A1
- Authority
- AU
- Australia
- Prior art keywords
- targeted
- macromolecules
- multivalent macromolecules
- targeted multivalent
- multivalent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
- A61K51/1227—Micelles, e.g. phospholipidic or polymeric micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
- A61K51/1234—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29430901P | 2001-05-30 | 2001-05-30 | |
| US60/294,309 | 2001-05-30 | ||
| US30910401P | 2001-07-31 | 2001-07-31 | |
| US60/309,104 | 2001-07-31 | ||
| US31243501P | 2001-08-15 | 2001-08-15 | |
| US60/312,435 | 2001-08-15 | ||
| US09/976,254 US20020071843A1 (en) | 2000-10-11 | 2001-10-11 | Targeted therapeutic agents |
| US09/976,254 | 2001-10-11 | ||
| PCT/US2002/017191 WO2002096367A2 (en) | 2001-05-30 | 2002-05-30 | Targeted multivalent macromolecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002314861A1 true AU2002314861A1 (en) | 2002-12-09 |
Family
ID=27501629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002314861A Abandoned AU2002314861A1 (en) | 2001-05-30 | 2002-05-30 | Targeted multivalent macromolecules |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1401818A2 (en) |
| JP (1) | JP2004535407A (en) |
| AU (1) | AU2002314861A1 (en) |
| WO (1) | WO2002096367A2 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002072011A2 (en) * | 2001-03-08 | 2002-09-19 | Targesome, Inc. | Stabilized therapeutic and imaging agents |
| MXPA04007124A (en) * | 2002-02-01 | 2004-10-29 | Omeros Corp | Compositions and methods for systemic inhibition of cartilage degradation. |
| US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
| US7211240B2 (en) | 2002-03-01 | 2007-05-01 | Bracco International B.V. | Multivalent constructs for therapeutic and diagnostic applications |
| US20050100963A1 (en) | 2002-03-01 | 2005-05-12 | Dyax Corporation | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
| US7794693B2 (en) | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
| US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
| CN1777439A (en) * | 2003-04-22 | 2006-05-24 | 研究及应用科学协会股份有限公司 | Somatostatin vectors |
| ITRM20040240A1 (en) * | 2004-05-13 | 2004-08-13 | Ist Naz Stud Cura Dei Tumori | CAMPTOTECINE CONJUGATED IN POSITION 7 WITH INTEGRINE ANTAGONISTS. |
| US8821859B2 (en) * | 2004-05-19 | 2014-09-02 | Agency For Science, Technology And Research | Methods and articles for the delivery of therapeutic agents |
| NL1027479C2 (en) * | 2004-10-21 | 2006-05-01 | Synvolux Ip B V | Protection of biologically active molecules with the help of amphiphiles. |
| EP1833512A1 (en) * | 2005-01-06 | 2007-09-19 | GE Healthcare AS | Optical imaging |
| JP4881327B2 (en) * | 2006-01-31 | 2012-02-22 | 大鵬薬品工業株式会社 | Liposome preparation of antitumor active substance |
| US20090169610A1 (en) * | 2006-02-03 | 2009-07-02 | Noboru Yamazaki | Liposome Preparation |
| EP1985298A1 (en) * | 2007-04-24 | 2008-10-29 | Azad Pharma AG | Ophtalmic oil-in-water emulsions containing prostaglandins |
| EP2643308B1 (en) * | 2010-11-23 | 2016-08-17 | Biophore India Pharmaceuticals Pvt. Ltd. | Process for the preparation of taurolidine and its intermediates thereof |
| EP2537532A1 (en) * | 2011-06-22 | 2012-12-26 | J. Stefan Institute | Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use |
| JP2014129318A (en) * | 2012-02-23 | 2014-07-10 | Canon Inc | Indocyanine green-containing particles and photoacoustic-imaging contrast agent including the same |
| EP2777715A1 (en) * | 2013-03-14 | 2014-09-17 | Centre National de la Recherche Scientifique (CNRS) | Particles comprising luminescent lanthanide complexes |
| ES2800524T3 (en) * | 2013-12-13 | 2020-12-30 | Mercury Asset Man Co Ltd | Image composition of articular cartilage |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5212075A (en) * | 1991-04-15 | 1993-05-18 | The Regents Of The University Of California | Compositions and methods for introducing effectors to pathogens and cells |
| US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
| US6132764A (en) * | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
| US6066123A (en) * | 1998-04-09 | 2000-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of bioavailability by use of focused energy delivery to a target tissue |
-
2002
- 2002-05-30 AU AU2002314861A patent/AU2002314861A1/en not_active Abandoned
- 2002-05-30 WO PCT/US2002/017191 patent/WO2002096367A2/en not_active Ceased
- 2002-05-30 EP EP02741784A patent/EP1401818A2/en not_active Withdrawn
- 2002-05-30 JP JP2002592880A patent/JP2004535407A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002096367A2 (en) | 2002-12-05 |
| EP1401818A2 (en) | 2004-03-31 |
| WO2002096367A3 (en) | 2003-03-06 |
| JP2004535407A (en) | 2004-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002308751A1 (en) | Authentication method | |
| AU2002309706A1 (en) | Novel meningitis conjugate vaccine | |
| AU2002314861A1 (en) | Targeted multivalent macromolecules | |
| AU2002351574A1 (en) | Improved self-chekout apparatus | |
| AU2002254558A1 (en) | Novel vaccine | |
| AU2002343312A1 (en) | Two fixed-beams tx-diversity | |
| AU2002366513A1 (en) | Scoring methodology | |
| AU2003285320A1 (en) | Vaccine | |
| AU2003237695A1 (en) | Authentication means | |
| AU2003237701A1 (en) | Vaccines | |
| AU2002345028A1 (en) | Authentication method | |
| AU2002303093A1 (en) | Mycobacterial vaccines | |
| AU2002321882A1 (en) | Multivalent synthetic vaccine for cancer | |
| AU2002256867A1 (en) | Bollard | |
| AUPR440001A0 (en) | Vaccine | |
| AU2002337263A1 (en) | Anti-coronavirus vaccine | |
| HK1062453A (en) | Vaccine | |
| HK1069982A (en) | Vaccine | |
| AU2001100504A4 (en) | Adjustable site peg | |
| AU2002336375A1 (en) | Improved conjugate vaccines | |
| AU2002100926A4 (en) | Paving product-ezypath | |
| AU2002302785A1 (en) | Vaccines | |
| AU2002253048A1 (en) | Novel vaccine | |
| AU2002253381A1 (en) | Methods | |
| AU2002256786A1 (en) | Methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |